These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2203303)

  • 1. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.
    Barbhaiya RH; Forgue ST; Gleason CR; Knupp CA; Pittman KA; Weidler DJ; Martin RR
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1118-22. PubMed ID: 2203303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.
    Barbhaiya RH; Forgue ST; Gleason CR; Knupp CA; Pittman KA; Weidler DJ; Movahhed H; Tenney J; Martin RR
    Antimicrob Agents Chemother; 1992 Mar; 36(3):552-7. PubMed ID: 1622165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
    Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.
    Barbhaiya RH; Knupp CA; Pfeffer M; Zaccardelli D; Dukes GM; Mattern W; Pittman KA; Hak LJ
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1387-91. PubMed ID: 1510432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of pharmacokinetic interaction between cefepime and amikacin in humans.
    Barbhaiya RH; Knupp CA; Pfeffer M; Pittman KA
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1382-6. PubMed ID: 1510431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers.
    Bächer K; Schaeffer M; Lode H; Nord CE; Borner K; Koeppe P
    J Antimicrob Chemother; 1992 Sep; 30(3):365-75. PubMed ID: 1452502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics, safety, and tolerance of cefepime administered as an intravenous bolus or as a rapid infusion.
    Garrelts JC; Wagner DJ
    Ann Pharmacother; 1999 Dec; 33(12):1258-61. PubMed ID: 10630824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects.
    Barbhaiya RH; Knupp CA; Tenney J; Martin RR; Weidler DJ; Pittman KA
    J Clin Pharmacol; 1990 Oct; 30(10):900-10. PubMed ID: 2229450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys.
    Forgue ST; Shyu WC; Gleason CR; Pittman KA; Barbhaiya RH
    Antimicrob Agents Chemother; 1987 May; 31(5):799-804. PubMed ID: 3606078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cefepime: a review.
    Van der Auwera P; Santella PJ
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():103-15. PubMed ID: 8150753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment.
    Cronqvist J; Nilsson-Ehle I; Oqvist B; Norrby SR
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2676-80. PubMed ID: 1482136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the pharmacokinetics of cefepime in children.
    Blumer JL; Reed MD; Knupp C
    Pediatr Infect Dis J; 2001 Mar; 20(3):337-42. PubMed ID: 11303847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime.
    Paulfeuerborn W; Müller HJ; Borner K; Koeppe P; Lode H
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1835-41. PubMed ID: 8239592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cefepime in cystic fibrosis patients.
    Huls CE; Prince RA; Seilheimer DK; Bosso JA
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1414-6. PubMed ID: 8363368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-proportional pharmacokinetics of cefepime in rats.
    Brindley CJ; Brodie RR; Cook SC; Oldfield PR; Chasseaud LF; Barbhaiya RH
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():9-14. PubMed ID: 1820942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of cefepime: a new extended-spectrum parenteral cephalosporin.
    Neu HC
    Am J Med; 1996 Jun; 100(6A):68S-75S. PubMed ID: 8678100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefepime clinical pharmacokinetics.
    Okamoto MP; Nakahiro RK; Chin A; Bedikian A
    Clin Pharmacokinet; 1993 Aug; 25(2):88-102. PubMed ID: 8403741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo.
    Mattie H; Sekh BA; van Ogtrop ML; van Strijen E
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2439-43. PubMed ID: 1489186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.